Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor types from three phase I/II trials of durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher pretreatment variant allele frequencies (VAF) were associated with poorer overall survival (OS) and other known prognostic factors, but not objective response, suggesting a prognostic role for patient outcomes. On-treatment reductions in VAF and lower on-treatment VAF were independently associated with longer progression-free survival and OS and increased objective response rate, but not prognostic variables, suggesting that on-treatment ctDNA dynamics are predictive of benefit from immune checkpoint blockade. Accordingly, we propose a concept of “molecular response” using ctDNA, incorporating both pretreatment and on-treatment VAF, that predicted long-term survival similarly to initial radiologic response while also permitting early differentiation of responders among patients with initially radiologically stable disease. Significance: In a pan-cancer analysis of immune checkpoint blockade, pretreatment ctDNA levels appeared prognostic and on-treatment dynamics predictive. A “molecular response” metric identified long-term responders and adjudicated benefit among patients with initially radiologically stable disease. Changes in ctDNA may be more dynamic than radiographic changes and could complement existing trial endpoints. This article is highlighted in the In This Issue feature, p. 1775
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, integration of longitudinal blood-based assays such as circulating-tumor DNA (ctDNA; ref. 216), which are easier to implement and less invasive as opposed to longitudinal tumor biopsies, is under investigation as a method to monitor responses to ICT.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Items 301–376 of 376
Phung, Q. H., Tsai, A. K., Park, B., Schat, R., Spong, R., Tsai, J., Kulkarni, A. A., Antonarakis, E. S., & Gupta, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1579364 · Cited by 1
Kuş, T., & Çiçin, İ. (2024) · Immunotherapy · doi:10.2217/imt-2023-0184 · Cited by 1
Öner, E., Saini, V. M., Cahill, C., O’Toole, H., Li, J. W., Gately, K. A., & Anagnostou, V. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1806868 · Cited by 1
Standish, L. J. (2022) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2022.22.556092 · Cited by 1
Kang, M., Kim, J., Park, J., & Yu, D. (2026) · Journal of Veterinary Science · doi:10.4142/jvs.25370 · Cited by 1
A Needle in a Haystack: The Precision of Liquid Biopsy in Finding Bone Tumors
Nohra, A., Awad, G., Khoury, J., & Boutros, M. (2026) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206402501251117070031 · Cited by 1
Barragan-Carillo, R., Mateos-Corella, S., Ortiz-Hidalgo, C., Izquierdo-Echavarri, E., Castillejos-Molina, R., Angel, M., Barragan-Arteaga, I., Flaig, T. W., & Bourlon, M. (2021) · ONCOLOGY · doi:10.46883/2021.25920932 · Cited by 1
The complexity of carcinosarcoma
Reddy, S. A. (2021) · ONCOLOGY · doi:10.46883/2021.25920934 · Cited by 1
Yang, C., Song, X., Sun, H., Chen, M., & Zhu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1947595 · Cited by 1
Wang, X., Li, Z., Chang, Y., Li, S., Wu, W., Chang, F., Chang, Y., Zhu, D., Gong, D., Zhang, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14457-6 · Cited by 1
Checkpoint-Inhibitoren – aktuelle Versorgungsstandards und Zukunftstrends
Reischer, A., Krüger, S., & von Bergwelt‐Baildon, M. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1303-8820 · Cited by 1
Cáncer de vejiga: diagnóstico y principios terapéuticos
Léon, P. (2024) · EMC - Urología · doi:10.1016/s1761-3310(24)49282-7 · Cited by 1
Paz-Ares, L. G., Garassino, M. C., Chen, Y., Reinmuth, N., Hotta, K., Poltoratskiy, A., Trukhin, D. V., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2024) · doi:10.1158/1078-0432.c.7077758.v2 · Cited by 1
Chandra, R., & Reznik, S. I. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005456 · Cited by 1
Liz’s Bali Journey Ends In Love In Elizabeth Gilbert’s Novel “Eat Pray Love”
Simanjuntak, L. (2011)
Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment
Masago, K., & Fujita, S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.002
Yu, J., Xu, G., Li, Y. C., Huang, M., Yang, L., & Peng, X. Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04525-9
Innovative Pharmacometric Approaches to Inform Drug Development and Clinical Use
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4503-4
Tripathy, S., Gaur, A., Jagadeb, M., Swarup, V., Gupta, N. M., Kumar, U., Das, S., & Jana, M. K. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2025.12.006
Wang, T., Mei, Y., Liu, S., Wang, H., Chen, M., & Han, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778522
Role of circulating tumour DNA in gastric cancer: a review
Naz, A., Peter, L. T., Blonski, W. C., & Mok, S. R. S. (2026) · Considerations in Medicine · doi:10.1136/conmed-2025-000019
Methods and statistics for high-throughput data in basic science
Mayhew, D. L., & Huber, K. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88423-5.00086-8
Yamada, T., Okuyama, K., Hamada, A., & Yanamoto, S. (2026) · Oral Oncology · doi:10.1016/j.oraloncology.2026.107958
Zengin, Z. B., Weipert, C. M., Salgia, N., Dizman, N., Hsu, J., Meza, L., Chehrazi‐Raffle, A., Muddasani, R., Salgia, S. K., Malhotra, J., et al. (2023) · doi:10.1158/1078-0432.c.6530498.v1
Muto, J., Sudo, T., Saya, H., & Hirose, Y. (2025) · Spinal Surgery · doi:10.2531/spinalsurg.39.36
Li, G., Huang, T., Li, J.-X., Liu, J., Gao, X., Yan, G., Yang, N., & Zhou, H. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2486381
Pacey, S., Linossi, C., Azizi, A. A., Dayimu, A., Machin, A., Demiris, N., Miremadi, A., O’Donovan, M., Mennea, P. D., Zhou, Z., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5209969/v1
Li, Q., Cristini, V., Gupta, A. K., Achour, I., Barrett, J. C., & Koay, E. J. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00254
Self-citationChong, X., Bai, Y., Liu, H., Yan, Z., Cong, L., Gong, J., Wang, Y., Chen, H., Cai, J., Chen, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4186786
Constructing a Predictive Model for PD-1 Blockade Therapy in Pan-Cancer Based on Machine LearningPreprint
Li, H., Li, S., Xiong, L., Yang, M., Dai, W., Luo, X., Liu, S., Xiao, D., Ning, B.-Y., Liu, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6317412/v1
A New Horizon in Cancer Care: Liquid Biopsy
Copur, M. S. (2021) · ONCOLOGY · doi:10.46883/2021.25920936
Kadefors, M., Nelson, A., Blomberg, E., Ståhlberg, A., Ny, L., & Bagge, R. O. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101079
Liu, X., Xie, Y., Ou, K., Zhang, X., Lu, C., Liu, J., & Yang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-585372/v1
Choksi, A., Varga, M. G., Farmer, T. E., Florou, V., Dill, D., Krabbe, K., Tsao, D., & Chen, A. M. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100669
Application of ctDNA in Colorectal Cancer Detection
王, 明. (2024) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2024.144062
Garassino, M. C., Cousin, S., Besse, B., Sacher, A., Orlov, S., Schenker, M., Felip, E., Gladkov, O. A., Messina, C. H., Majumdar, A., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.04.003
Can Liquid Biopsy be Used to Explore Future Precision Medicine for Solid Tumors?
Kikuchi, H., & Takeuchi, H. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10873-7
Nakamura, Y., Esaki, T., Nishina, T., Shinozaki, E., Taniguchi, H., Kato, T., Komatsu, Y., Yuki, S., Kato, K., Wakabayashi, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108578
Biomarkers for Cancer Immunotherapy: Advances, Challenges, and Clinical Applications
Abbasi, A. A., & Haq, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219882
Sur, D. G., Lang‐Schwarz, C., Herpe, F. V., Rasschaert, G., Weeda, Y. A., Littlefield, N. G., Gu, Q., Li, N., Hardas, A., Hida, A. I., et al. (2026) · Histopathology · doi:10.1111/his.70307
Molecular characterization of Chinese patients with small bowel adenocarcinoma
Jin, B., Lv, B., Yan, Z., Li, W., Song, H., Cui, H., Liu, Y., Zhong, B., Shen, X., Li, X., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03441-4
Immunosénescence, inflammation et immunothérapies
Naigeon, M. (2022) · theses.fr (ABES) · doi:10.70675/f0b0b5e9zc57dz4931z82c0z1510abbc8c2c
Arangham, P., Mandha, M., & Hopak, N. V. (2026) · Genetics and Molecular Research · doi:10.4238/s7k7k033
Isaacs, D. J., Park, C., Zha, L., Liang, R., Godoy, L. A., Stollenwerk, N. S., Wei, D., Chang, K. Y., Rajappa, P., & Li, T. (2026) · Cancers · doi:10.3390/cancers18213456
Jiang, T., Chen, J., Xu, X., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.17798421
Sorbini, M. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
de Miguel‐Pérez, D., Russo, A., Arrieta, O., Ak, M., Barrón, F., Gunasekaran, M., Mamindla, P., Lara‐Mejía, L., Peterson, C. B., Er, M. E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959758
Harel, N., Hamilton, A., Cope, T. C. T., Harris, W., Lefkovits, Y., Middleton, M., Desai, J., & Tie, J. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01269-2
Thakor, P. R., Bed, V. B. C. B., & Patel, M. J. (2026) · Medico Research Chronicles
Systematic benchmarking of multi-modal approaches for tumor-naïve ctDNA detection and quantificationPreprint
Qi, T., Odinokov, D., Lakshmanan, L. N., Grachet, N. G., Lou, M., Saelee, S. L., Garcia-Montoya, G., Wong, P. M., Rahman, R. C., Asgharian, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.19.733293
Gatsis, A., Stouras, I., Lallas, K., Tseriotis, V., Tsolakidis, D., Elemes, S., Mauri, D., Timotheadou, E. T., & Lazaridis, G. (2026) · Current Oncology · doi:10.3390/curroncol33110688
Deploying liquid intelligence in cancer: Finding answers in our blood
George, J. M., Wielenga, A. J., Iyer, M. K., & Chinnaiyan, A. M. (2026) · Cell · doi:10.1016/j.cell.2026.10.024
Khandavalli, C. K., Yashwanth, J. N., Erothi, B., & Devi, D. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3556
Phuong, L. N., Fina, F., Greillier, L., Bakhmach, A., Tomasini, P., Deville, J.-L., Zakrasjek, R., Della-Negra, L., Boutonnet, A., Ginot, F., et al. (2026) · HAL
Monitoring Molecular Residual Disease in Colorectal Cancer Using Tumor-Informed ctDNA Analysis
Cho, W. C., Wang, Y., Yao, Q., Berntsen, T., Yeung, G., Tang, P., Wittkop, T., Weng, L., Ng, L., & Foo, D. C.-C. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.080218
Li, Y., Deng, H., & Wu, X. (2026) · Discover Oncology · doi:10.1007/s12672-026-04723-9
Hasenleithner, S. O., Rao, S., Yu, J. Q., Tan, Y., Sheriff, F. S., Winn, J. S., Borghaei, H., Edelman, M. J., Giri, A., Astsaturov, I. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27136078
Rivas, M. D. M., & Pascual, J. (2026) · Future Oncology · doi:10.1080/14796694.2026.2727260
In the literature: October 2020
Gambardella, V., Bruixola, G., Alfaro‐Cervelló, C., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001048
Brown, D. B., & Agarwal, R. (2020) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2020.09.027
Pembrolizumab bei Mikrosatelliteninstabilität
Reinshagen, M. (2021) · Gastro-News · doi:10.1007/s15036-020-2285-6
Bu, Y., Sheng, Z., Deng, K., Wu, S., Xu, S., Guo, G., Zhang, Z., Liu, G., Yu, J., Gao, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1413932/v1
Self-citationZeng, Y., Liu, Y., Zhuang, G., Hao, W., Li, L., Ma, W., Gu, P., Xie, W., Zheng, X., Ruan, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1649710/v1
Voss, M. H., Azad, A., Hansen, A. R., Gray, J. E., Welsh, S. J., Song, X., Kuziora, M. A., Meinecke, L., Blando, J. M., Achour, I., et al. (2023) · doi:10.1158/1078-0432.c.6532443
大塚, 観., & Otsuka, K. (2024) · Iwate Medical University Repository (Iwate Medical University)
Liquid biopsy application in cancer diagnostics and scientific research
Ćato, T., Vukovic, M., & Cavic, M. (2025) · doi:10.5281/zenodo.18803676
Kuchiba, A., Nishino, J., Yachida, S., 角南久仁子, Koyama, T., Yamamoto, N., Kato, M., & Shibata, T. (2026) · Statistical Applications in Genetics and Molecular Biology · doi:10.1515/sagmb-2024-0020
Gu, R.-T., Li, X., Cheng, W., Wang, X.-W., Jin, H., & Liu, T. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i6.117851
Zhang, Q., Su, J. M., Huang, S., Guo, L., Dai, D., Zhang, M., Lyu, S., Chen, Z., & Chang, J. (2026) · Translational Cancer Research · doi:10.21037/tcr-2026-0594
Self-citationSubbiah, V., & Sharon, E. (2026) · Cancer · doi:10.1002/cncr.70556
Linossi, C., Azizi, A. A., Machin, A., Dayimu, A., Demiris, N., White, H., Miremadi, A., O’Donovan, M., Godfrey, E. M., Mennea, P. D., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01827-9
Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report
Cruz, M. C., Rodriguez‐Justo, M., Humphries, A., Plumb, A., Antoniou, A., Monahan, K. J., Runswick, S. K., Capone, A., Antonucci, L., Garzia, I., et al. (2026) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-25-32
Circulating tumor DNA to direct adjuvant immunotherapy across mismatch repair-deficient solid tumors
Janjigian, Y. Y., Lumish, M. A., Foote, M. B., Socolow, F., Perissinotto, E., Darmofal, M., Madwed, M., Segal, M., Yaqubie, A., Capanu, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.11.005
Self-citationWong, Z. Y., Wonsettler, N., Martin, E. A., McChesney, G. R., Barrett, C., & Kolodney, J. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.2011971
Metadata
- Authors
- Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D.
- Affiliations
- 1Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, Maryland.
- Memorial Sloan Kettering Cancer Center (US)
- 3Early Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.
- AstraZeneca (United States) (US)
- 5Division of Molecular Carcinogenesis and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
- Corresponding author
- Hellmann, Matthew D.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-12-01
- Volume
- 10
- Issue
- 12
- Pages
- 1842-1853
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8358981
- OpenAlex
- W3049083268
- Cited by
- 348
- References
- 53
- Citations by year
- 2026: 31 · 2025: 72 · 2024: 60 · 2023: 70 · 2022: 54 · 2021: 54 · 2020: 6
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca (NCT01693562, NCT02087423, NCT02261220)
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
- Damon Runyon Cancer Research Foundation (CI-98-18)
- Parker Institute for Cancer Immunotherapy
- NIH (T32-CA009207, K30-UL1TR00457)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- circulating tumor DNA, immune checkpoint blockade, durvalumab, tremelimumab, variant allele frequency, molecular response, prognostic factors, predictive biomarkers, overall survival, progression-free survival, objective response rate, pan-cancer analysis, CTLA-4 blockade
- MeSH terms
- Circulating Tumor DNA, Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.